Company told several of us at the 2015 Biotech Showcase that they don't want to partner with anyone until Brilacidin is in or done with phase III. They feel they'll get a substantially better deal at that time. The discussion was about Brilacidin ph2b ABSSSI.
Regarding uplist... I don't have enough information to really comment on that other than believing price dropped too much. Timing was off and in hindsight it's easy to say they shouldn't have mentioned it until it was a done deal.
In Reply to 'sixmilliondollarbios' Thank you for the cogent reply. That's an interesting perspective on the K trial as well as Brilacidin OM. I do not have confidence in Prurisol. But what bothers me is the up listing issue and why not partner Brilacidin for ABSSSI?
News 
Market Data 
Discover 
AI
